Intensive blood pressure/glucose control in type 2 diabetes: why is it so difficult to decrease coronary heart disease?
Reaven
G M
GM
Division of Endocrinology, Stanford University Medical Centre, CA 94305, USA.
D000959:Antihypertensive Agents / Q000627:therapeutic use; D001786:Blood Glucose; D001795:Blood Pressure Determination; D003327:Coronary Disease / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D015994:Incidence; D008297:Male; D012307:Risk Factors; D006113:United Kingdom / Q000453:epidemiology
D000959:Antihypertensive Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents